ICON Clinical Research (U.K.) No. 6 Limited 09743789 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is in the year under review was that of a holding company. Digita Accounts Production Advanced 6.30.9574.0 true true true false false false false false 09743789 2024-01-01 2024-12-31 09743789 2024-12-31 09743789 bus:OrdinaryShareClass2 2024-12-31 09743789 bus:OrdinaryShareClass3 2024-12-31 09743789 bus:OrdinaryShareClass4 2024-12-31 09743789 bus:OrdinaryShareClass5 2024-12-31 09743789 bus:Consolidated 2024-12-31 09743789 core:RetainedEarningsAccumulatedLosses 2024-12-31 09743789 core:ShareCapital 2024-12-31 09743789 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 09743789 bus:FRS102 2024-01-01 2024-12-31 09743789 bus:Audited 2024-01-01 2024-12-31 09743789 bus:FullAccounts 2024-01-01 2024-12-31 09743789 bus:RegisteredOffice 2024-01-01 2024-12-31 09743789 bus:CompanySecretary1 2024-01-01 2024-12-31 09743789 bus:Director2 2024-01-01 2024-12-31 09743789 bus:Director3 2024-01-01 2024-12-31 09743789 bus:OrdinaryShareClass2 2024-01-01 2024-12-31 09743789 bus:OrdinaryShareClass3 2024-01-01 2024-12-31 09743789 bus:OrdinaryShareClass4 2024-01-01 2024-12-31 09743789 bus:OrdinaryShareClass5 2024-01-01 2024-12-31 09743789 bus:Consolidated 2024-01-01 2024-12-31 09743789 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 09743789 bus:Agent1 2024-01-01 2024-12-31 09743789 core:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 09743789 core:ShareCapital 2024-01-01 2024-12-31 09743789 core:Subsidiary1 2024-01-01 2024-12-31 09743789 core:Subsidiary1 1 2024-01-01 2024-12-31 09743789 core:Subsidiary2 2024-01-01 2024-12-31 09743789 core:Subsidiary2 1 2024-01-01 2024-12-31 09743789 core:Subsidiary3 2024-01-01 2024-12-31 09743789 core:Subsidiary3 1 2024-01-01 2024-12-31 09743789 core:UKTax 2024-01-01 2024-12-31 09743789 countries:EnglandWales 2024-01-01 2024-12-31 09743789 2023-12-31 09743789 core:RetainedEarningsAccumulatedLosses 2023-12-31 09743789 core:ShareCapital 2023-12-31 09743789 2023-01-01 2023-12-31 09743789 2023-12-31 09743789 bus:OrdinaryShareClass2 2023-12-31 09743789 bus:OrdinaryShareClass3 2023-12-31 09743789 bus:OrdinaryShareClass4 2023-12-31 09743789 bus:OrdinaryShareClass5 2023-12-31 09743789 core:RetainedEarningsAccumulatedLosses 2023-12-31 09743789 core:ShareCapital 2023-12-31 09743789 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 09743789 core:CostValuation 2023-12-31 09743789 core:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 09743789 core:ShareCapital 2023-01-01 2023-12-31 09743789 core:Subsidiary1 1 2023-01-01 2023-12-31 09743789 core:Subsidiary2 1 2023-01-01 2023-12-31 09743789 core:Subsidiary3 1 2023-01-01 2023-12-31 09743789 core:UKTax 2023-01-01 2023-12-31 09743789 2022-12-31 09743789 core:RetainedEarningsAccumulatedLosses 2022-12-31 09743789 core:ShareCapital 2022-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 09743789

ICON Clinical Research (U.K.) No. 6 Limited
Annual Report and Financial Statements
for the Year Ended 31 December 2024

ICON Clinical Research (U.K.) No. 6 Limited

Contents

Company Information | 1
Strategic Report | 2
Directors' Report | 3
Statement of Directors' Responsibilities | 4
Independent Auditor's Report | 5 to 7
Profit and Loss Account | 8
Balance Sheet | 9
Statement of Changes in Equity | 10
Notes to the Financial Statements | 11 to 16

ICON Clinical Research (U.K.) No. 6 Limited

Company Information

Directors | S Hollywood E Lyons

Company secretary | E Fox

Registered office | 3rd Floor, North & South Wings 100 Longwater Avenue Green Park Reading Berkshire RG2 6GP

Auditors | Hazlewoods LLP Windsor House Bayshill Road Cheltenham GL50 3AT

ICON Clinical Research (U.K.) No. 6 Limited

Strategic Report for the Year Ended 31 December 2024

The directors present their strategic report for the year ended 31 December 2024.

Principal activity

The principal activity of ICON Clinical Research (U.K.) No. 6 Limited ("the Company") in the year under review was that of a holding company.

Business review
There has been no significant change in the operations or performance of the Company during the year under review.
Principal risks and uncertainties
The Company's activities are exposed to financial and business risks as noted below. The Company has in place risk management policies that seek to limit to adverse effect of these risks on the financial performance of the Company.
Business risk
The key business risks and uncertainties affecting the Company are considered to relate to ongoing compliance with current and future regulations and legislation affecting the sector.
Financial risk management objectives and policies
A principal factor which cause risk and uncertainty for the Company is the development performance and financial position of the ICON plc group (of which the Company is a member). The consolidated financial statements of ICON plc are available from the Companies Registration Office, Bloom House, Gloucester Place lower, Dublin 1, Ireland.

Results and dividends

The results for the year, which are set out in the profit and loss account, show an operating loss of £246 (2023 - £7,377). At 31 December 2024, the company has net assets of £32,143,808 (2023 - £32,145,059). The directors do not recommend the payment of a dividend.

Approved by the Board on 23 December 2025 and signed on its behalf by:

E Lyons
Director

ICON Clinical Research (U.K.) No. 6 Limited

Directors' Report for the Year Ended 31 December 2024

The directors present their report and the financial statements for the year ended 31 December 2024.

Directors

The directors who held office during the year were as follows:

S Hollywood

E Lyons

Going concern

Management intend to liquidate the company in the near future. The financial statements have therefore not been prepared on a going concern basis. This has not resulted in any material adjustments to the amounts in the financial statements.

Disclosure of information to the auditors

Each director has taken steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the Company's auditors are aware of that information. The directors confirm that there is no relevant information that they know of and of which they know the auditors are unaware.

Reappointment of auditors

Hazlewoods LLP have expressed their willingness to continue in office.

Approved by the Board on 23 December 2025 and signed on its behalf by:

E Lyons
Director

ICON Clinical Research (U.K.) No. 6 Limited

Statement of Directors' Responsibilities

The directors are responsible for preparing the Strategic Report, Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to:

• | select suitable accounting policies and apply them consistently;
• | make judgements and accounting estimates that are reasonable and prudent;
• | state whether applicable UK Accounting Standards has been followed, subject to any material departures disclosed and explained in the financial statements; and
• | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Board on 23 December 2025 and signed on its behalf by:

E Lyons
Director

ICON Clinical Research (U.K.) No. 6 Limited

Independent Auditor's Report to the Members of ICON Clinical Research (U.K.) No. 6 Limited

Opinion

We have audited the financial statements of ICON Clinical Research (U.K.) No. 6 Limited (the 'Company') for the year ended 31 December 2024, which comprise the Profit and Loss Account, Balance Sheet, Statement of Changes in Equity, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

• | give a true and fair view of the state of the Company's affairs as at 31 December 2024 and of its loss for the year then ended;
• | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
• | have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

The financial statements have been prepared on a basis which is not a going concern basis due to management's intention to liquidate the company after the year end which is expected to occur within 12 months of the year end.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

ICON Clinical Research (U.K.) No. 6 Limited

Independent Auditor's Report to the Members of ICON Clinical Research (U.K.) No. 6 Limited

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

• | the information given in the Strategic Report and Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

• | the Strategic Report and Directors' Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

• | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
• | the financial statements are not in agreement with the accounting records and returns; or
• | certain disclosures of directors' remuneration specified by law are not made; or
• | we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
We considered the nature of the company’s industry and its control environment and reviewed the company’s documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.
We obtained an understanding of the legal and regulatory framework that the company operates in and identified the key laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements, including the UK Companies Act and tax legislation, and, those that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company’s ability to operate or to avoid a material penalty.
We discussed among the audit engagement team regarding the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.

ICON Clinical Research (U.K.) No. 6 Limited

Independent Auditor's Report to the Members of ICON Clinical Research (U.K.) No. 6 Limited

In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgments made in accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.
In addition to the above, our procedures to respond to the risks identified included the following:

• | reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;

• | performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatements due to fraud;

• | enquiring of management concerning actual and potential litigation and claims and instances of non-compliance with laws and regulations; and

• | reading minutes of meetings of those charged with governance.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities is available on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report
This report is made solely to the Company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Martin Howard (Senior Statutory Auditor)
For and on behalf of Hazlewoods LLP, Statutory Auditor
Windsor House
Bayshill Road
Cheltenham
GL50 3AT

6 January 2026

ICON Clinical Research (U.K.) No. 6 Limited

Profit and Loss Account for the Year Ended 31 December 2024

| Note | 2024 £ | 2023 £
Turnover |  | - | -
Cost of sales |  | 1,267 | 600
Gross profit |  | 1,267 | 600
Administrative expenses |  | (1,513) | (7,977)
Operating loss | 3 | (246) | (7,377)
Income from shares in group undertakings |  | - | 5,536,885
Interest payable and similar charges | 4 | (3,397) | -
(Loss)/profit before tax |  | (3,643) | 5,529,508
Taxation | 7 | 2,392 | (26,807)
(Loss)/profit for the financial year |  | (1,251) | 5,502,701

The above results were derived from continuing operations.

The Company has no other comprehensive income for the year.

ICON Clinical Research (U.K.) No. 6 Limited

(Registration number: 09743789)
Balance Sheet as at 31 December 2024

| Note | 2024 £ | 2023 £
Fixed assets |  |  |
Investments | 8 | 780 | 780
Current assets |  |  |
Debtors | 9 | 32,011,726 | 32,008,781
Cash at bank and in hand |  | 141,441 | 166,098
|  | 32,153,167 | 32,174,879
Creditors: Amounts falling due within one year | 10 | (10,139) | (30,600)
Net current assets |  | 32,143,028 | 32,144,279
Net assets |  | 32,143,808 | 32,145,059
Capital and reserves |  |  |
Called up share capital | 11 | 210 | 210
Profit and loss account |  | 32,143,598 | 32,144,849
Total equity |  | 32,143,808 | 32,145,059

Approved and authorised by the Board on 23 December 2025 and signed on its behalf by:

E Lyons
Director

ICON Clinical Research (U.K.) No. 6 Limited

Statement of Changes in Equity for the Year Ended 31 December 2024

| Share capital £ | Profit and loss account £ | Total £
At 1 January 2024 | 210 | 32,144,849 | 32,145,059
Loss for the year | - | (1,251) | (1,251)
At 31 December 2024 | 210 | 32,143,598 | 32,143,808

| Share capital £ | Profit and loss account £ | Total £
At 1 January 2023 | 210 | 26,642,148 | 26,642,358
Profit for the year | - | 5,502,701 | 5,502,701
At 31 December 2023 | 210 | 32,144,849 | 32,145,059

ICON Clinical Research (U.K.) No. 6 Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

| 1 | General information

The Company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
3rd Floor, North & South Wings
100 Longwater Avenue
Green Park
Reading
Berkshire
RG2 6GP

| 2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements were prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the Company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Group accounts not prepared

The Company has taken advantage of the exemption in section 401 of the Companies Act 2006 from the requirement to prepare consolidated financial statements, on the grounds that it is included in the consolidated accounts of ICON plc.

Basis other than going concern

Management intend to liquidate the company in the near future. The financial statements have therefore not been prepared on a going concern basis. This has not resulted in any material adjustments to the amounts in the financial statements.

Judgements and estimation uncertainty

These financial statements do not contain any significant judgements or estimation uncertainty.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the initial transaction dates.
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

ICON Clinical Research (U.K.) No. 6 Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates taxable income.

Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the Company. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.
The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

ICON Clinical Research (U.K.) No. 6 Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Financial instruments

Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the Company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.
Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.
A non-financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.
The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.
Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.
For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.
For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.
Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

ICON Clinical Research (U.K.) No. 6 Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

| 3 | Operating profit

Arrived at after charging/(crediting):

| 2024 £ | 2023 £
Foreign exchange gains | (1,267) | (600)

| 4 | Interest payable and similar expenses

| 2024 £ | 2023 £
Interest expense on other finance liabilities | 3,397 | -

| 5 | Directors and employees

The average number of persons employed by the company (including directors) during the year, analysed by category was as follows:

| 2024 No. | 2023 No.
Directors | 2 | 2
Administration and support | - | 1
| 2 | 3

Directors remuneration has been borne by another group entity.

| 6 | Auditors' remuneration

| 2024 £ | 2023 £
Audit of the financial statements | 2,220 | 2,100

ICON Clinical Research (U.K.) No. 6 Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

| 7 | Taxation

Tax charged/(credited)/(credited) in the profit and loss account

| 2024 £ | 2023 £
Current taxation |  |
UK corporation tax adjustment to prior periods | (2,392) | 26,807

The tax on profit before tax for the year is lower than the standard rate of corporation tax in the UK (2023 - lower than the standard rate of corporation tax in the UK) of 25% (2023 - 23.52%).
The differences are reconciled below:

| 2024 £ | 2023 £
(Loss)/profit before tax | (3,643) | 5,529,508
Corporation tax at standard rate | (911) | 1,300,571
(Decrease)/increase in UK and foreign current tax from adjustment for prior periods | (2,392) | 26,807
Effect of revenues exempt from taxation | - | (1,302,306)
Tax increase arising from group relief | - | 7,377
Deferred tax expense/(credit) from unrecognised tax loss or credit | 911 | (5,642)
Total tax (credit)/charge | (2,392) | 26,807

| 8 | Investments

| 2024 £ | 2023 £
Investments in subsidiaries | 780 | 780

Subsidiaries | £
Cost and carrying amount
At 1 January 2024 and at 31 December 2024 | 780

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the Company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking | Registered office | Holding | Proportion of voting rights and shares held
|  |  | 2024 | 2023
Subsidiary undertakings
ICON Clinical Research (U.K.) No. 4 Limited | England and Wales |
Ordinary
100%
100%
Medpass International Pty Ltd | Australia |
Ordinary
100%
100%
ICON Clinical Research (U.K.) No. 5 Limited | England and Wales |
Ordinary
100%
100%

The principal activity of Medpass International Pty Limited is the provision of representative services in Australia.
During the year, ICON Clinical Research (U.K.) No.4 Limited entered solvent liquidation.

ICON Clinical Research (U.K.) No. 6 Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

| 9 | Debtors

| 2024 £ | 2023 £
Amounts owed by group undertakings | 32,010,581 | 32,008,781
Corporation tax asset | 1,145 | -
| 32,011,726 | 32,008,781

Amounts due from group companies relates to a non-interest bearing loan which is repayable at the discretion of the borrower.

| 10 | Creditors

| 2024 £ | 2023 £
Due within one year |  |
Accrued expenses | 10,139 | 10,920
Corporation tax liability | - | 19,680
| 10,139 | 30,600

| 11 | Share capital

Allotted, called up and fully paid shares

| 2024 | 2023
| No. | £ | No. | £
A Ordinary shares of £1 each | 147 | 147 | 147 | 147
B Ordinary shares of £1 each | 21 | 21 | 21 | 21
C Ordinary shares of £1 each | 21 | 21 | 21 | 21
D Ordinary shares of £1 each | 21 | 21 | 21 | 21
| 210 | 210 | 210 | 210

Rights, preferences and restrictions

The different classes of shares referred to above carry separate rights to dividends but, in all other significant respects, rank pari passu.

| 12 | Group membership and controlling parties

The Company is wholly owned subsidiary undertaking of ICON Investments Limited, which is controlled by ICON plc. The ultimate parent company is ICON plc. The largest and smallest group into which the results of the Company are consolidated is that headed by ICON plc, the consolidated financial statements of which may be obtained from the Companies registered Office, Bloom House, Gloucester Place Lower, Dublin 1, Ireland.